alexa Cancer Vaccination, Will You Have To Pay The Toll?
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Cancer Vaccination, Will You Have To Pay The Toll?

Sean M. Gregory1,2, John A. West1,2 and Blossom Damania1,2,3*

1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC27599, USA

2Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC27599, USA

3UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

*Corresponding Author:
Blossom Damania
Lineberger Comprehensive Cancer Center
University of North Carolina, Chapel Hill, NC27599, USA
Tel: (919) 843- 6011
Fax: (919) 966¬9673
E-mail: [email protected]

Received date: September 10, 2011; Accepted date: November 06, 2011; Published date: November 10, 2011

Citation: Gregory SM, West JA, Damania B (2011) Cancer Vaccination, Will You Have To Pay The Toll? J Vaccines Vaccin S1:001. doi: 10.4172/2157-7560.S1-001

Copyright: © 2011 Gregory SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Cancer vaccines based on patient-derived, autologous immune cells are actively being pursued as a novel strategy to utilize the body’s natural defenses against malignancy. Harnessing the ability of the immune system to fight cancer involves overcoming many obstacles including tumor-specific targeting, overcoming tolerance, and generating effective tumoricidal responses. Co-administration of immune activating adjuvants may hold the key to breaking through several of these barriers. Toll-like receptors (TLR) are pathogen sensors of the innate immune system that activate proinflammatory responses to fight infection and initiate adaptive immune responses. TLRs are increasingly being explored in combination with cancer vaccine strategies since they may have the potential to enhance immunotherapy by promoting tumor-specific immunity. This review will focus on recent basic and clinical research on the use of TLR agonists in cancer therapy.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords